↓ Skip to main content

Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria

Overview of attention for article published in Malaria Journal, November 2017
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
33 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria
Published in
Malaria Journal, November 2017
DOI 10.1186/s12936-017-2109-0
Pubmed ID
Authors

Valerie M. Crowley, Kodjo Ayi, Ziyue Lu, Karen T. Liby, Michael Sporn, Kevin C. Kain

Abstract

Cerebral malaria (CM) is a severe complication of Plasmodium falciparum infection associated with high mortality and neurocognitive impairment in survivors. New anti-malarials and host-based adjunctive therapy may improve clinical outcome in CM. Synthetic oleanane triterpenoid (SO) compounds have shown efficacy in the treatment of diseases where inflammation and oxidative stress contribute to pathogenesis. A derivative of the SO 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), CDDO-ethyl amide (CDDO-EA) was investigated for the treatment of severe malaria in a pre-clinical model. CDDO-EA was evaluated in vivo as a monotherapy as well as adjunctive therapy with parenteral artesunate in the Plasmodium berghei strain ANKA experimental cerebral malaria (ECM) model. CDDO-EA alone improved outcome in ECM and, given as adjunctive therapy in combination with artesunate, it significantly improved outcome over artesunate alone (p = 0.009). Improved survival was associated with reduced inflammation, enhanced endothelial stability and blood-brain barrier integrity. Survival was improved even when administered late in the disease course after the onset of neurological symptoms. These results indicate that SO are a new class of immunomodulatory drugs and support further studies investigating this class of agents as potential adjunctive therapy for severe malaria.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 33 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 21%
Student > Ph. D. Student 6 18%
Researcher 4 12%
Other 3 9%
Student > Bachelor 3 9%
Other 4 12%
Unknown 6 18%
Readers by discipline Count As %
Medicine and Dentistry 7 21%
Biochemistry, Genetics and Molecular Biology 4 12%
Agricultural and Biological Sciences 4 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Computer Science 2 6%
Other 4 12%
Unknown 9 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2017.
All research outputs
#15,483,026
of 23,007,887 outputs
Outputs from Malaria Journal
#4,503
of 5,598 outputs
Outputs of similar age
#203,515
of 325,276 outputs
Outputs of similar age from Malaria Journal
#101
of 108 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,598 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,276 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 108 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.